Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05096650
Other study ID # CMRPG5K0121
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date November 30, 2021
Est. completion date August 31, 2022

Study information

Verified date September 2021
Source Chang Gung Memorial Hospital
Contact Yau-Li Huang, MD
Phone +886-3-3196200
Email henryhuang0219@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Photoaging is characterized by cellular changes and alterations in dermal extracellular matrix proteins with degeneration of connective tissue caused by intrinsic and extrinsic factors. The clinical manifestations of photoaging included wrinkles, pigmented changes, tissue loss, and sagging. Autologous platelet-rich plasma is a preparation of platelets in concentrated plasma from peripheral blood. The α granules of platelets contained many growth factors. According to previous literature, growth factors in platelet-rich plasma directly stimulate fibroblast proliferation to boost collagen production. It has also been shown to modulate extracellular matrix metabolism and remodeling by increasing the expression of specific matrix metalloproteinases. In review of previous literatures, there was only limited researches of platelet-rich plasma for treatment of photoaging. Therefore, the present study was conducted for analyzing the efficacy and safety of autologous platelet-rich plasma in photoaging therapy.


Description:

Autologous platelet-rich plasma is a preparation of platelets in concentrated plasma from peripheral blood. The α granules of platelets contained many growth factors, such as platelet-derived growth factor, transforming growth factor, vascular endothelial growth factor, and epithelial growth factor. These growth factors can trigger intracellular signaling cascades that ultimately alter gene expression and protein synthesis. Clinically, autologous platelet-rich plasma has been applied for treatment of hair loss, chronic wounds, and atrophic scars. Photoaging is characterized by cellular changes and alterations in dermal extracellular matrix proteins with degeneration of connective tissue caused by intrinsic and extrinsic factors. The clinical manifestations of photoaging included wrinkles, pigmented changes, tissue loss, and sagging. The therapeutic modalities of photoaging included energy-based device, filler injection, and surgical treatment. However, there are some limitations and drawbacks of these therapies. For example, filler injection may cause foreign body granuloma, vascular occlusions, or tissue necrosis. Surgical treatment is an invasive procedure which may cause hematoma, infection, or scar formation. According to previous literature, growth factors in platelet-rich plasma directly stimulate fibroblast proliferation to boost collagen production. It has also been shown to modulate extracellular matrix metabolism and remodeling by increasing the expression of specific matrix metalloproteinases. Platelet-rich plasma-enhanced expression of matrix metalloproteinases -1 and -3 helps clear photodamaged extracellular matrix components and allow for a better quality, more organized collagen meshwork. This process helps soften fine lines and minimize scarring. In addition, transforming growth factor and epithelial growth factor in platelet-rich plasma are known to modulate keratinocyte propagation and migration as well as repair barrier function. In review of previous literatures, there was only limited researches of platelet-rich plasma for treatment of photoaging. Therefore, the present study was conducted for analyzing the efficacy and safety of autologous platelet-rich plasma in photoaging therapy.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 15
Est. completion date August 31, 2022
Est. primary completion date August 31, 2022
Accepts healthy volunteers No
Gender All
Age group 20 Years and older
Eligibility Inclusion criteria: 1. Men or female patients older than 20 years old with facial photoaging (Glogau Scale type II) 2. The photoaging severity of bilateral face is symmetric. Exclusion criteria: 1. Patients with thrombocytopenia, coagulopathy, hematopoietic malignancy. 2. Patients with severe inflammation over treated area, malignancy, keloid, or poor wound healing history. 3. Patients had received laser, radiofrequency, ultherapy over treated area within 6 months. 4. Patients had received botulism or filler injection over treated area within 12 months. 5. Patients had received plastic surgery over treated area within 12 months. 6. Patients had severe psychiatric disorders with poor control. 7. Patients with other diseases which are not suitable for receiving platelet rich plasma (PRP) injection therapy.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
mesotherapy of platelet rich plasma and platelet poor plasma
Each case will receive 3 sessions of injection therapies with one month interval. Each case will receive platelet rich plasma therapy on one side of the face. The other side of the face was treated with platelet poor plasma.

Locations

Country Name City State
Taiwan Chang Gung Memorial Hospital Taipei

Sponsors (1)

Lead Sponsor Collaborator
Chang Gung Memorial Hospital

Country where clinical trial is conducted

Taiwan, 

References & Publications (4)

Cameli N, Mariano M, Cordone I, Abril E, Masi S, Foddai ML. Autologous Pure Platelet-Rich Plasma Dermal Injections for Facial Skin Rejuvenation: Clinical, Instrumental, and Flow Cytometry Assessment. Dermatol Surg. 2017 Jun;43(6):826-835. doi: 10.1097/DSS — View Citation

Elnehrawy NY, Ibrahim ZA, Eltoukhy AM, Nagy HM. Assessment of the efficacy and safety of single platelet-rich plasma injection on different types and grades of facial wrinkles. J Cosmet Dermatol. 2017 Mar;16(1):103-111. doi: 10.1111/jocd.12258. Epub 2016 — View Citation

Lee ZH, Sinno S, Poudrier G, Motosko CC, Chiodo M, Saia W, Gothard D, Thomson JE, Hazen A. Platelet rich plasma for photodamaged skin: A pilot study. J Cosmet Dermatol. 2019 Feb;18(1):77-83. doi: 10.1111/jocd.12676. Epub 2018 May 31. — View Citation

Mehryan P, Zartab H, Rajabi A, Pazhoohi N, Firooz A. Assessment of efficacy of platelet-rich plasma (PRP) on infraorbital dark circles and crow's feet wrinkles. J Cosmet Dermatol. 2014 Mar;13(1):72-8. doi: 10.1111/jocd.12072. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Global Aesthetic Improvement Scale To assess the global aesthetic improvement in appearance compared to pretreatment (minimum: -1, worse; maximum: 3, very much improved) 3 months after the last session of treatment
Primary Fitzpatrick wrinkle scale To assess the severity of wrinkles of photoaging areas (minimum: 1, mild; maximum: 9, severe) 3 months after the last session of treatment
Primary Wrinkle Severity Rating scale To assess the severity of wrinkles of photoaging areas (minimum: 1, absent; maximum: 5, extreme) 3 months after the last session of treatment
Secondary The scores of rhytids in VISIA system Apply the scores of different aging domains in VISIA system for evaluating the therapeutic response.
(minimum: 1, worse; maximum: 100, severe)
before the 1st, 2nd and 3rd sessions of treatment as well as 1 and 3 months after the last session of treatment
Secondary The scores of texture in VISIA system Apply the scores of different aging domains in VISIA system for evaluating the therapeutic response.
(minimum: 1, worse; maximum: 100, severe)
before the 1st, 2nd and 3rd sessions of treatment as well as 1 and 3 months after the last session of treatment
Secondary The scores of pores size in VISIA system Apply the scores of different aging domains in VISIA system for evaluating the therapeutic response.
(minimum: 1, worse; maximum: 100, severe)
before the 1st, 2nd and 3rd sessions of treatment as well as 1 and 3 months after the last session of treatment
Secondary The scores of pigment spots in VISIA system Apply the scores of different aging domains in VISIA system for evaluating the therapeutic response.
(minimum: 1, worse; maximum: 100, severe)
before the 1st, 2nd and 3rd sessions of treatment as well as 1 and 3 months after the last session of treatment
Secondary The scores of brownish spots in VISIA system Apply the scores of different aging domains in VISIA system for evaluating the therapeutic response.
(minimum: 1, worse; maximum: 100, severe)
before the 1st, 2nd and 3rd sessions of treatment as well as 1 and 3 months after the last session of treatment
See also
  Status Clinical Trial Phase
Completed NCT05433233 - Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension N/A
Recruiting NCT06032065 - Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD) Phase 3
Completed NCT05293730 - Trial of the Impact of the Electronic Frailty Integrated With Social Needs N/A
Recruiting NCT03932162 - Gene Expression Changes In Young and Geriatric Skin Early Phase 1
Completed NCT04064528 - Effects of Age on Amino Acid Delivery to Tendon N/A
Completed NCT03366129 - Blood-Brain Barrier Disruption in People With White Matter Hyperintensities Who Have Had a Stroke
Completed NCT06029920 - Influence of Overground Walking on Biomarkers, Cognitive Function, and Quality of Life in Elderly With Mild Cognitive Impairment N/A
Recruiting NCT05566938 - Study to Design a Precision Nutrition Strategy at a Group Level in the Elderly N/A
Recruiting NCT05543980 - Leg Heat Therapy in Elderly Individuals Phase 2
Completed NCT04894929 - Comprehensive Geriatric Assessment in the Monitoring of Functional Improvement N/A
Not yet recruiting NCT06071130 - Emotion, Aging, and Decision Making N/A
Enrolling by invitation NCT04641663 - Multi-target Dietary Supplement Tolerability in an Aging Population (MTDSST) N/A
Completed NCT04088006 - The Evaluation of Efficacy and Safety of Hyaluronic Acid Injection on Skin Moisturization and Elasticity N/A
Completed NCT03695081 - Patient Pathway Pharmacist - Optimal Drug-related Care N/A
Recruiting NCT05424263 - Acetate and Age-associated Arterial Dysfunction Phase 2
Completed NCT05601713 - Mitigating Heat-induced Physiological Strain and Discomfort in Older Adults Via Lower Limb Immersion and Neck Cooling N/A
Completed NCT04551339 - Zinc Versus Multivitamin Micronutrient Supplementation in the Setting of COVID-19 N/A
Recruiting NCT04997577 - Speech Perception and High Cognitive Demand N/A
Completed NCT05922475 - Efficacy of Pre-sleep or Post-exercise Protein During 12 Weeks of Resistance Exercise Training N/A
Completed NCT04015479 - Peanut Protein Supplementation to Augment Muscle Growth and Improve Markers of Muscle Quality and Health in Older Adults N/A